Cardiovascular Disease· Topic 2.4 Dysrhythmias and conduction defects· 2.4.23

Catecholaminergic polymorphic ventricular tachycardia

Catecholaminergic polymorphic ventricular tachycardia is an inherited disorder of calcium handling causing exercise- or emotion-induced bidirectional or polymorphic ventricular tachycardia in structurally normal hearts with a normal resting ECG. Management is high-dose beta-blockade, flecainide, exercise restriction, and an ICD for high-risk patients.

4 min read22 practice questions7 key factsSubscriber article
  • Topic review
    The full article, organized the way the exam asks it.
  • ABIM-format MCQs
    Vignettes with an explanation for every wrong answer.
  • Key facts
    The numbers and thresholds worth memorizing, up front.
  • AI tutor
    MedBrain answers the question you're stuck on.

What this article covers

  • Overview

    Definition: catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited disorder of intracellular calcium handling causing adrenergically triggered bidirectional or polymorphic…

  • Epidemiology

    Typically presents in childhood or adolescence.

  • Risk factors

    RYR2 (autosomal dominant) and CASQ2 (autosomal recessive) mutations and family history.

  • Pathophysiology

    Abnormal calcium release: mutations in the ryanodine receptor (RYR2) or calsequestrin (CASQ2) cause excessive diastolic calcium leak from the sarcoplasmic reticulum under adrenergic stimulation.

  • Clinical features

    Exertional or emotional syncope. Palpitations with exercise.

  • Differential diagnosis

    Long QT syndrome (especially LQT1): exertional syncope, distinguished by a prolonged corrected QT interval on the resting ECG, which is normal in CPVT (Long QT syndrome).

  • Diagnosis

    Establish by reproducible adrenergically induced bidirectional or polymorphic VT with a normal resting ECG and structurally normal heart: the diagnostic basis is exercise or catecholamine provocation…

  • Management

    First-line, start high-dose beta-blockade and restrict triggers: give a non-selective beta-blocker (nadolol 1 to 2 mg/kg/day, continued indefinitely) and restrict competitive and strenuous exercise.

  • Complications

    Bidirectional and polymorphic VT and ventricular fibrillation.

  • Prognosis

    Good with adherent high-dose beta-blockade and flecainide.

  • Prevention

    High-dose beta-blockade (nadolol 1 to 2 mg/kg/day) and exercise restriction.

Read the whole article

Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.